Literature DB >> 24379895

Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge.

Gregory C Whitlock1, Arpaporn Deeraksa2, Omar Qazi3, Barbara M Judy2, Katherine Taylor2, Katie L Propst4, Angie J Duffy4, Kate Johnson3, G Barrie Kitto5, Katherine A Brown6, Steven W Dow4, Alfredo G Torres7, D Mark Estes7.   

Abstract

Burkholderia mallei and B. pseudomallei are Gram-negative pathogenic bacteria, responsible for the diseases glanders and melioidosis, respectively. Furthermore, there is currently no vaccine available against these Burkholderia species. In this study, we aimed to identify protective proteins against these pathogens. Immunization with recombinant B. mallei Hcp1 (type VI secreted/structural protein), BimA (autotransporter protein), BopA (type III secreted protein), and B. pseudomallei LolC (ABC transporter protein) generated significant protection against lethal inhaled B. mallei ATCC23344 and B. pseudomallei 1026b challenge. Immunization with BopA elicited the greatest protective activity, resulting in 100% and 60% survival against B. mallei and B. pseudomallei challenge, respectively. Moreover, sera from recovered mice demonstrated reactivity with the recombinant proteins. Dendritic cells stimulated with each of the different recombinant proteins showed distinct cytokine patterns. In addition, T cells from immunized mice produced IFN-γ following in vitro re-stimulation. These results indicated therefore that it was possible to elicit cross-protective immunity against both B. mallei and B. pseudomallei by vaccinating animals with one or more novel recombinant proteins identified in B. mallei.

Entities:  

Keywords:  B. mallei; B. pseudomallei; Burkholderia; intranasal infection; subunit vaccination; vaccine

Year:  2010        PMID: 24379895      PMCID: PMC3874274          DOI: 10.1016/j.provac.2010.03.013

Source DB:  PubMed          Journal:  Procedia Vaccinol


  24 in total

1.  Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes.

Authors:  A Krogh; B Larsson; G von Heijne; E L Sonnhammer
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

2.  Improved prediction of signal peptides: SignalP 3.0.

Authors:  Jannick Dyrløv Bendtsen; Henrik Nielsen; Gunnar von Heijne; Søren Brunak
Journal:  J Mol Biol       Date:  2004-07-16       Impact factor: 5.469

3.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei.

Authors:  L E Bryan; S Wong; D E Woods; D A Dance; W Chaowagul
Journal:  Can J Infect Dis       Date:  1994-07

Review 5.  Therapeutic potential of Toll-like receptor 9 activation.

Authors:  Arthur M Krieg
Journal:  Nat Rev Drug Discov       Date:  2006-06       Impact factor: 84.694

6.  Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis.

Authors:  Michelle Nelson; Joann L Prior; M Stephen Lever; Helen E Jones; Timothy P Atkins; Richard W Titball
Journal:  J Med Microbiol       Date:  2004-12       Impact factor: 2.472

7.  CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice.

Authors:  Yao-Shen Chen; Yu-Shan Hsiao; Hsi-Hsun Lin; Yin Liu; Ya-Lei Chen
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

8.  Construction of a reporter system to study Burkholderia mallei type III secretion and identification of the BopA effector protein function in intracellular survival.

Authors:  Gregory C Whitlock; D Mark Estes; Glenn M Young; Briana Young; Alfredo G Torres
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12       Impact factor: 2.184

9.  Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.

Authors:  David N Harland; Karen Chu; Ashraful Haque; Michelle Nelson; Nicola J Walker; Mitali Sarkar-Tyson; Timothy P Atkins; Benjamin Moore; Katherine A Brown; Gregory Bancroft; Richard W Titball; Helen S Atkins
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Isolation and characterization of Pseudomonas pseudomallei flagellin proteins.

Authors:  P J Brett; D C Mah; D E Woods
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more
  22 in total

Review 1.  Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Authors:  L Morici; A G Torres; R W Titball
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

Review 2.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

3.  Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Authors:  Christopher L Hatcher; Tiffany M Mott; Laura A Muruato; Elena Sbrana; Alfredo G Torres
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

4.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

5.  Development of reagents and assays for the detection of pathogenic Burkholderia species.

Authors:  Omar Qazi; Mridula Rani; Annie J Gnanam; Thomas W Cullen; Christopher M Stead; Haley Kensing; Kate McCaul; Sarah Ngugi; Joann L Prior; Alexandria Lipka; Judit M Nagy; C Whitlock Gregory; Barbara M Judy; Sarah V Harding; Richard W Titball; Sachdev S Sidhu; M Stephen Trent; G Barrie Kitto; Alfredo Torres; D Mark Estes; Brent Iverson; George Georgiou; Katherine A Brown
Journal:  Faraday Discuss       Date:  2011       Impact factor: 4.008

6.  The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei.

Authors:  Mary N Burtnick; Paul J Brett; Sarah V Harding; Sarah A Ngugi; Wilson J Ribot; Narisara Chantratita; Angelo Scorpio; Timothy S Milne; Rachel E Dean; David L Fritz; Sharon J Peacock; Joanne L Prior; Timothy P Atkins; David Deshazer
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

7.  Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.

Authors:  Laura A Muruato; Daniel Tapia; Christopher L Hatcher; Mridul Kalita; Paul J Brett; Anthony E Gregory; James E Samuel; Richard W Titball; Alfredo G Torres
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

Review 8.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

Review 9.  Burkholderia cepacia Complex Vaccines: Where Do We Go from here?

Authors:  Gonzalo A Pradenas; Brittany N Ross; Alfredo G Torres
Journal:  Vaccines (Basel)       Date:  2016-04-15

10.  A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.

Authors:  Anthony E Gregory; Barbara M Judy; Omar Qazi; Carla A Blumentritt; Katherine A Brown; Andrew M Shaw; Alfredo G Torres; Richard W Titball
Journal:  Nanomedicine       Date:  2014-09-03       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.